NeerajAgarwalMD

PubMed

• 651 citations
  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
  Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring
  The Lancet. Oncology. 2016-07-01
• 29 citations
  Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
  Fadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
  JCO Precision Oncology. 2021-07-22
• 783 citations
  Olaparib for Metastatic Castration-Resistant Prostate Cancer.
  Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore
  The New England Journal of Medicine. 2020-05-28

Journal Articles

• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer  
  Maha Hussain, Neeraj Agarwal, Przemyslaw Twardowski, The New England Journal of Medicine
• Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma  
  Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
• Immunologic Therapy of Renal Cell Carcinoma  
  Agarwal N, Fishman M, Oncology & Hematology Review, 1/1/2014
• Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma  
  Fishman M, Hutson T, Agarwal N, Jonasch E, Oncology & Hematology Review, 1/1/2012
• Editorial comment on "a Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Prior to Radical Prostatectomy in High-Risk Patients"  
  Agarwal N, Journal of Urology, 1/1/2011
• Join now to see all

Books/Book Chapters

• Lost in Translation: Barriers in Incentives for Translational Research 
  Chapter: "Integrating Emerging Science into Clinical Practice: Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer" 
  Kollepara SS, Tantravahi SK, Batten J, Agarwal NEditors: Lopaczynski W, Srivastava R, and Maksymowicz W.World Scientific Publishing Co Pte. Ltd, Singapore2014
• Multidisciplinary Approach to Prostate Cancer 
  Chapter: "Metastatic Castrate Resistant Prostate cancer: Role of Androgen Signaling Inhibitors" 
  Poole A, Alva A, Batten JA, Agarwal NEditors: Dicker AP, Trabulsi EJ, Kelly WK.Demos Medical Publishing, New York2014
• Cancer Vaccines 
  Chapter: "Development of novel immune interventions for genitor-urinary cancers" 
  Agarwal N, Vogelzang NJEditors: Adrian Bot, Mihail Obrocea & Francesco Marincola.Informa Healthcare, London, UKEdition 1st,2011
• Williams Hematology 
  Chapter: Methemoglobinemia and Other Dyshemoglobinemias 
  Agarwal N, Prchal JTEditors: Kaushansky K, Lichtman M, Beutler E.McGraw-Hill, New YorkEdition 8th,2009
• Disorders of Hemoglobin. Genetics, Pathophysiology, and Clinical Management 
  Chapter: Dyshemoglobinemia 
  Agarwal N, Nagel RL, Prchal JTEditors: Steinberg MH, Forget BG, Higgs DR, Nagel RL.Cambridge University Press, New YorkEdition 2nd,2009
• Wintrobe's Clinical Hematology 
  Chapter: "Miscellaneous Causes of Thrombocytopenia" 
  Agarwal N, Rodgers GMEditors: Greer JP, Foerster J, Rodgers GM et al.Lippincott Williams & Wilkins (LWW)Edition 12th,2009
• Hypoxia and Circulation 
  Chapter: "Genetic Mechanisms Underlying Regulation of Hemoglobin Mass" 
  Agarwal N, Gordeuk VR, Prchal JTEditors: Roach RC, Wagner PD, and Hackett PH.Springer, New York2007
• Join now to see all

Abstracts/Posters

• Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vasc...
  Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with h...
  Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• The international metastatic renal cell carcinoma database consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously t...
  Ko JJ, Xie W, Heng DY, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Harshman LC, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal ..., J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Databa...
  Heng DY, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaish..., J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma.
  Tsao CK, Agarwal N, Apolo AB, Lee KM, Godbold JH, Oh WK, Galsky MD, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• The Effect of Prior Abiraterone (Abi) Use on the Efficacy of Enzalutamide (Enza) in Men with mCRPC.
  Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan U, Agarwal N, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery RB, Galsky MD, Chi KN, Antonara..., J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).
  Stenehjem DD, Parikh K, Batten JA, VanAtta J, Crispin H, Sagesser D, Grossmann K, Tantravahi SK, Samlowski W, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Clinical benefit (CB) of high dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC).
  Agarwal N, Parikh K, Tantravahi SK, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Stenehjem DD, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• The association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2).
  Batten JA, Samlowski W, Parikh K, Sendilnathan A, Van Atta J, Batten JA, Sagesser D, Grossmann K, Tantravahi SK, Stenehjem DD, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Conditional survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD-IL2).
  Parikh K, Stenehjem DD, Sendilnathan A, Crispin H, VanAtta J, Batten JA, Sagesser D, GrossmannK, Samlowski W, Tantravahi SK, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors.
  Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer...
  Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tej..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal...
  Albiges L, Xie W, Lee JL, Rini B, Srinivas S, Bjarnason G, Ernst S, Wood L, Vaishamayan U, Rha SH, Agarwal N, Yuasa T, Pal SK, Koutsoukos K, Fay AP, Preston M, Cho E, ..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-inv...
  Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versu...
  Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sens...
  Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, ..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hor...
  Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC).
  Tantravahi SK, Stenehjem DD, Agarwal A, Kollepara SL, Batten JA, Ward M, Albertson D, Wang JF, Liu T, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Physical activity and quality of life associations with telomere length among senior female cancer survivors enrolled in a Tai Chi Chih trial.
  Campo RA, Light KC, O'Connor K, Nakamura Y, Lipschitz D, LaStayo P, Agarwal N, & Kinney AY, Society of Behavioral Medicine (SBM) Annual Meeting, San Francisco, CA, 1/20/2013
• Effects of a 12-week Qigong intervention on fatigue and global distress in senior prostate cancer survivors and their family members.
  Campo RA, O'Connor K, LaStayo P, Light KC, Agarwal N, Kinney AY, American Psychosomatic Society (APS) Annual Meeting, Miami, FL, 1/13/2013
• Effects of a 12-week Qigong intervention on fatigue and global distress in senior prostate cancer survivors and their family members.
  Campo RA, O'Connor K, LaStayo P, Light KC, Agarwal N, & Kinney AY, American Psychosomatic Society Annual Meeting, Miami, FL, 1/13/2013
• Phase I Study of Histone Deacetylase Inhibitor Belinostat in Combination with Warfarin in Patients with Solid Tumors or Hematological Malignancies.
  Agarwal N, Wade M, Batten J, Davidson C, Sun SL, Sharma S, AACR Annual Meeting, Washington, DC, 1/8/2013
• Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15.
  Cannon-Albright LA, Teerlink CC, Agarwal N, AACR Annual Meeting, Washington, DC, 1/8/2013
• 18F-FDG and FLT PET for early prediction of response to Sunitinib in metastatic renal cell carcinoma.
  Zollinger L, Morton K, Agarwal N, Kadrmas D, Christian P, Beardmore B, Butterfield R, Hoffman J, Society of Nuclear Medicine & Molecular Imaging (SNMMI), 2013 60th Annual Meeting, Vancouver, BC, Canada, 1/8/2013
• Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial ca...
  Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Fougeray R, Niegisch G, Wong YN, Sridhar SS, Sternberg CN, Sonpavde G, J Clin Oncol; Genitourinary Cancers Symposium, Orlando, FL, February 14-16, 2013, 1/1/2013
• Join now to see all

Lectures

• TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant ... 
  2019 ASCO Annual Meeting - 6/1/2019

Other

• Perspective opinion on "Gleason score associated with time to development of neuroendocrine prostate cancer. Wang HT et al. J Clin Oncol. 2014 Oct 20;32(30):3383-90" 
  Agarwal N, HemOnc Today
  Helio.com
  1/30/2014
• "Beyond the abstract- Development of novel immune interventions for prostate cancer" 
  Agarwal N, Vogelzang NJ, UroToday
  UroToday.com
  1/15/2012
• Management of Thrombotic Microangiopathy with Underlying Malignancy. 
  Lim HY, Werner TL, Agarwal N, Rodgers GM, Review Series Oncology
  1/1/2008
• "Case of the Quarter: Society of Hematopathology" 
  Wada D, Agarwal N, Lim M
  http://socforheme.org/caseqtr.htm
  1/1/2005
• DRESS syndrome associated with cephalosporin therapy. 
  Hussain I, Agarwal N, E-Letter in British Medical Journal
  http://bmj.bmjjournals.com/cgi/eletters/326/7403/1377
  1/1/2003
• Join now to see all